Objective. Effector CD81 T cell function is impaired in systemic lupus erythematosus (SLE) and is associated with a compromised ability to fight infections. Signaling lymphocytic activation molecule family member 7 (SLAMF7) engagement has been shown to enhance natural killer cell degranulation. This study was undertaken to characterize the expression and function of SLAMF7 on CD81 T cell subsets isolated from the peripheral blood of SLE patients and healthy subjects.
Objective. Effector CD81 T cell function is impaired in systemic lupus erythematosus (SLE) and is associated with a compromised ability to fight infections. Signaling lymphocytic activation molecule family member 7 (SLAMF7) engagement has been shown to enhance natural killer cell degranulation. This study was undertaken to characterize the expression and function of SLAMF7 on CD81 T cell subsets isolated from the peripheral blood of SLE patients and healthy subjects.
Methods. CD81 T cell subset distribution, SLAMF7 expression, and expression of cytolytic enzymes (perforin, granzyme A [GzmA], and GzmB) on cells isolated from SLE patients and healthy controls were analyzed by flow cytometry. CD107a expression and interferon-g (IFNg) production in response to viral antigenic stimulation in the presence or absence of an anti-SLAMF7 antibody were assessed by flow cytometry. Antiviral cytotoxic activity in response to SLAMF7 engagement was determined using a flow cytometry-based assay.
Results. The distribution of CD81 T cell subsets was altered in the peripheral blood of SLE patients, with a decreased effector cell subpopulation. Memory CD81 T cells from SLE patients displayed decreased amounts of SLAMF7, a surface receptor that characterizes effector CD81 T cells. Ligation of SLAMF7 increased CD81 T cell degranulation capacity and the percentage of IFNgproducing cells in response to antigen challenge in SLE patients and healthy controls. Moreover, SLAMF7 engagement promoted cytotoxic lysis of target cells in response to stimulation with viral antigens.
Conclusion. CD81 T cell activation in response to viral antigens is defective in SLE patients. Activation of SLAMF7 through a specific monoclonal antibody restores CD81 T cell antiviral effector function to normal levels and thus represents a potential therapeutic option in SLE.
Profound abnormalities characterize T cells from patients with systemic lupus erythematosus (SLE) (1, 2) . Even though CD41 T cells have been extensively studied, the role of CD81 T cells in SLE is less well understood. Studies suggest a defect in cytotoxic CD81 T cell activity in SLE and an accelerated disease in lupus-prone mice in which the major killing pathways of cytotoxic CD81 T cells have been deleted (3) (4) (5) . Additionally, SLE has been associated with defective cytotoxic responses against foreign antigens, an abnormality considered to contribute to the increased rate of infections, the leading cause of mortality in SLE (6) (7) (8) .
Signaling lymphocytic activation molecule (SLAM) family members are type I transmembrane glycoprotein cell surface receptors that deliver downstream signals upon their engagement and modulate the magnitude of the immune response (9) . SLAM family member 7 (SLAMF7; CS1, CRACC, CD319) is expressed on natural killer (NK) cells, NK T cells, CD81 T cells, and subsets of B cells (10) . SLAMF7 acts as a self-ligand through the binding of the N-terminal Ig domain of SLAMF7 (10) . In NK cells, SLAMF7 uses the adaptor protein Ewing's sarcoma/FLI1-activated transcript 2 (EAT-2) to promote downstream signaling, while other SLAMF molecules preferentially bind to SLAMF-associated protein (11) .
SLAMF7 has been extensively studied in patients with multiple myeloma, a malignant disorder of plasma cells. A monoclonal antibody (mAb) directed against SLAMF7 has been shown to eliminate myeloma cells by activating NK cells and by stimulating antibody-dependent cellular cytotoxicity (12) (13) (14) . SLAMF molecules, and their downstream adaptor protein SLAMF-associated protein, have been suggested to play a role in SLE pathogenesis and to represent a potential therapeutic target (15) (16) (17) . However, limited data are available concerning the role of SLAMF7 in SLE, and some studies have proposed that SLAMF7 can play a role in the pathogenesis of the disease (18, 19) . The gene encoding SLAMF7 is located on chromosome 1 within the 1q23 locus, a region known to be associated with an increased susceptibility to SLE (20) . SLAMF7 expression has been reported to be altered in NK cells, plasmacytoid dendritic cells, and a subset of B cells in SLE patients (18, 19) , but the role and function of SLAMF7 in SLE CD81 T cells has not been established.
In the present study, we show that the frequency of effector CD81 T cells is decreased in the peripheral blood of SLE patients compared to healthy controls. In addition, we demonstrate that the expression of SLAMF7 is decreased in SLE CD81 T cells and that the presence of SLAMF7 characterizes cytotoxic CD81 T cells. More importantly, engagement of SLAMF7 with a specific mAb enhances the degranulation and cytotoxicity of CD81 T cells in response to viral peptides. Despite the reduced SLAMF7 expression on SLE CD81 effector T cells, activation of SLAMF7 via an anti-SLAMF7 mAb restores CD81 T cell antiviral effector function to normal levels and, therefore, represents a potential therapeutic option to enhance immune response against foreign antigens.
MATERIALS AND METHODS
Patients and controls. SLE patients (n 5 79) were diagnosed according to the American College of Rheumatology classification criteria (21) and were recruited from the Division of Rheumatology at Beth Israel Deaconess Medical Center. Age-, sex-, and ethnicity-matched healthy individuals were chosen as controls. Disease activity was measured using the SLE Disease Activity Index (SLEDAI) (22) (Table 1 ). Informed consent was obtained as approved by the Institutional Review Board after the nature and possible consequences of the studies were explained, in compliance with the Declaration of Helsinki.
Cell isolation. Peripheral blood mononuclear cells (PBMCs) were enriched by density-gradient centrifugation (Lymphocyte Separation Medium; Corning Life Sciences). T cells were isolated by negative selection (RosetteSep; StemCell Technologies).
Flow cytometric analysis. Cells were stained to distinguish live and dead cells (Zombie Aqua or Zombie NIR Fixable Viability Kit; BioLegend), and then labeled for surface antibodies. Cells were permeabilized using a Cytofix/Cytoperm kit (BD Biosciences) and stained for cytokines and/or cytotoxic enzymes. Data were acquired with a SORP LSR II flow cytometer (BD Biosciences) and analyzed using FlowJo software (version 10.1r5; Tree Star).
Degranulation assay. Cryopreserved PBMCs (2 3 10 6 ) were stimulated for 6 hours in 1 ml of complete RPMI (RPMI 1640 supplemented with 10% fetal bovine serum, 100 mg/ml streptomycin, and 100 units/ml penicillin) in the presence of GolgiPlug (1 ml/ml; BD Biosciences) and GolgiStop (1 ml/ml; BD Biosciences), CD107a (4 ml/ml; BioLegend), and CEF (cytomegalovirus [CMV], Epstein-Barr virus [EBV], and influenza virus) peptide mix (3 mg/ml) or staphylococcal enterotoxin B (SEB; 1 mg/ml) as a positive control. When indicated, cells were also stimulated with anti-SLAMF7 mAb or a mouse IgG2b isotype control antibody (5 mg/ml; BioLegend), in the presence of a goat anti-mouse IgG crosslinker (EMD Millipore). At the end of the stimulation, cells were stained to distinguish live and dead cells (Zombie Aqua or Zombie NIR Fixable Viability Kit), then stained for surface antibodies with CD3 (BD Horizon BUV395 anti-human CD3), CD4 (PerCP eFluor 710-conjugated anti-human CD4; eBioscience), and CD8 (PerCPconjugated anti-human CD8; BioLegend), fixed/permeabilized (Cytofix/Cytoperm kit), and stained for interferon-g (IFNg) (Alexa Fluor 647-conjugated anti-human IFNg; BioLegend). Cells were then analyzed using a SORP LSR II flow cytometer and FlowJo software (version 10.1r5).
Flow cytometry-based assay for measuring CD81 T cell cytotoxic activity in response to anti-SLAMF7 mAb treatment. Freshly isolated PBMCs were cultured in the presence of CEF peptide mix (5 mg/ml) and interleukin-2 (IL-2) (20 IU/ml; PeproTech) for 6 days in complete RPMI. On day 3, half of the cell culture medium was replaced with fresh complete RPMI. On day 6, effector CD81 T cells were isolated by negative selection using magnetic sorting (human CD81 T cell isolation kit; Miltenyi Biotec). Cells were resuspended at a concentration of 10 6 /ml. Six serial dilutions were performed. From each dilution, half of the cells were treated with anti-SLAMF7 mAb (5 mg/ml) and a goat anti-mouse IgG crosslinker, while the other half were treated with an IgG isotype control and a goat anti-mouse IgG crosslinker. One hundred microliters of each CD81 T cell preparation was seeded in duplicate in a 96-well U-bottomed plate.
Freshly isolated autologous CD41 T cells sorted by magnetic negative selection (human CD41 T cell isolation kit; Miltenyi Biotec) were used as a target. Half of the CD41 T cells were labeled with 5,6-carboxyfluorescein succinimidyl ester (CFSE) 0.2 mM (CFSE high) and were pulsed with CEF peptide (5 mg/ml) for 45 minutes at 378C in complete RPMI. The other half of the CD41 T cells were labeled with CFSE 0.02 mM (CFSE low) and were used as a control to determine nonspecific background cell death. CFSE-high and -low CD41 T cells were mixed at a 1:1 ratio and resuspended at a concentration of 2 3 10 5 cells/ml. One hundred microliters of target CD41 T cells was added to each dilution of CD81 T cells. Cell mixtures were incubated for 6 hours at 378C.
After incubation, cells were stained to distinguish live and dead cells (Zombie Aqua Fixable Viability Kit), stained for CD4 (allophycocyanin [APC]-conjugated anti-human CD4 antibody; BioLegend) and CD8 (APC/Cy7-conjugated anti-human CD8 antibody; BioLegend), and analyzed by flow cytometry. Aqua-positive staining indicated dead cells. The percentage of target cell lysis in response to effector CD81 T cells was expressed as (% of Aqua1 pulsed CD41 T cells) 2 (% of Aqua1 unpulsed CD41 T cells).
Real-time quantitative reverse transcriptase-polymerase chain reaction (RT-PCR). Total RNA was extracted using an RNeasy Mini kit (Qiagen). Reverse transcription was performed from 500 ng of total RNA using a High-Capacity cDNA Archive Kit (Applied Biosystems). Quantitative RT-PCR was performed with 40 cycles at 948C (for 12 seconds) and 608C (for 60 seconds) using SYBR Green (LightCycler 4800 SYBR Green I Master kit; Roche). The comparative C t method was used to quantify transcripts relative to the endogenous control gene b-actin. Primer sequences were as follows: for EAT-2, forward 5 0 -TGTGCCTCTGTGTCTCGTTTA-3 0 and reverse 5 0 -ACCACCATCCCCTGATTTGG-3 0 ; and for bactin, forward 5 0 -AGAGCTACGAGCTGCCTGAC-3 0 and reverse 5 0 -AGCACTGTGTTGGCGTACAG-3 0 . Statistical analysis. Statistical analysis was performed using Student's t-test, corrected with the Holm-Sidak method. For multiple comparisons, statistical analysis was performed using one-way analysis of variance, followed by post hoc analysis 
RESULTS
Skewed distribution of CD81 T cell subsets in the peripheral blood of SLE patients. We analyzed the distribution of CD81 T cell subsets in the peripheral blood of 45 SLE patients with varying levels of disease activity and 41 healthy controls by assessing the cell surface expression of CCR7 and CD45RA. This allowed us to distinguish 4 differentiated CD81 T cell subsets, i.e., naive (CCR71 CD45RA1), central memory (CCR71CD45RA2), effector memory (CCR72CD45RA2), and terminally differentiated effector memory (CCR72CD45RA1) cells (23) ( Figure 1A ). The frequency of effector memory CD81 T cells was reduced in SLE patients compared to healthy controls, while naive CD81 T cells were enriched ( Figure  1B) . Moreover, the skewed distribution of CD81 T cells correlated with disease activity. Patients with active disease (defined as a SLEDAI score of $4) displayed a significant increase in naive CD81 T cells compared to patients with inactive disease (defined as a SLEDAI score of ,4) and compared to healthy controls ( Figure 1C ). In contrast, the frequency of central memory and effector memory CD8+ T cells was significantly decreased in patients with active disease compared to healthy controls ( Figures 1D and E) .
We observed a significant linear correlation between decreased number of terminally differentiated effector memory CD81 T cells and the SLEDAI score, which is associated with an increased frequency of CD81 T cells expressing naive markers (see Supplementary Figure 1 , available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley. com/doi/10.1002/art.40038/abstract). Of note, there was no difference in the percentage of total CD81 T cells between SLE patients and controls (see Supplementary Figure 2 , available on the Arthritis & Rheumatology web site at http:// onlinelibrary.wiley.com/doi/10.1002/art.40038/abstract).
Decreased SLAMF7 expression in CD81 T cells from SLE patients. Expression of SLAMF7 was examined in T cells isolated from SLE patients (n 5 16-27) and healthy controls (n 5 13-22). SLAMF7 was mostly expressed by CD81 T cells, as well as double-negative T cells, a T cell subset that expresses CD3 but has lost CD4 and CD8 expression (Figure 2A and Supplementary Figure 3A , available on the Arthritis & Rheumatology web site at http:// onlinelibrary.wiley.com/doi/10.1002/art.40038/abstract). In contrast, expression of SLAMF7 on CD41 T cells was very low. Expression of SLAMF7 was reduced in CD81 T cells and double-negative cells isolated from SLE patients compared to healthy controls (Figure 2A ).
Reduced SLAMF7 expression correlated with disease activity. SLE patients with active disease displayed less SLAMF7 expression than patients with inactive disease ( Figure 2B and Supplementary Figure 4 , available on the Arthritis & Rheumatology web site at http:// onlinelibrary.wiley.com/doi/10.1002/art.40038/abstract).
Because the distribution of CD81 T cell subsets was altered in SLE patients, we examined the expression of SLAMF7 in each differentiated CD81 T cell subset (naive, central memory, effector memory, and terminally differentiated effector memory cells). We observed that SLAMF7 expression increased during cell differentiation. Its expression was low in naive CD81 T cells, whereas most effector memory and terminally differentiated effector memory cells expressed SLAMF7 ( Figure 2C and Supplementary Figure 3B ). Importantly, each of the CD81 T cell subsets from SLE patients displayed decreased amounts of SLAMF7 compared to controls ( Figure 2C ). SLAMF7 expression was decreased among CD81 T cells isolated from SLE patients with active disease compared to those from patients with inactive disease ( Figure 2D and Supplementary Figure 3C and Supplementary Figure 4) .
Because it has previously been reported that SLAMF7 binds to EAT-2 in NK cells to transmit downstream signaling (11), we assessed the expression of EAT-2 in SLAMF72 CD81 and SLAMF71 CD81 T cells by quantitative PCR. We did not detect any EAT-2 gene expression in CD81 T cells (see Supplementary Figure 5 , available on the Arthritis & Rheumatology web site at http:// onlinelibrary.wiley.com/doi/10.1002/art.40038/abstract).
In summary, SLAMF7 expression increases during the differentiation of CD81 T cells and is mostly expressed by effector memory and terminally differentiated effector memory CD81 T cells. Moreover, SLAMF7 expression is decreased in SLE CD81 T cells compared to healthy controls.
Expression of SLAMF7 by effector CD81 cytotoxic T cells. To further examine the properties of SLAMF71 CD81 T cells, we assessed the coexpression of SLAMF7 and cytolytic enzymes (perforin, granzyme A [GzmA], and GzmB) in CD81 T cells isolated from the peripheral blood of SLE patients (n 5 18) and controls (n 5 15). Expression of the cytolytic enzymes perforin, GzmA, and GzmB was found to be restricted to SLAMF71 CD81 T cells ( Figure 3 ). As previously described (7), an altered expression of cytolytic enzymes was found in SLE patients compared to healthy controls. Perforin and GzmB expression was reduced in SLE patients, while GzmA expression was slightly increased.
In summary, SLAMF7 expression defines cytotoxic effector CD81 T cells, and its expression is decreased in SLE and is associated with an altered expression of cytotoxic CD81 T cell enzymes. Expression of cytolytic enzymes was also examined in differentiated subsets of CD81 T cells. As expected, expression of cytolytic enzymes was higher in effector cells (especially effector memory and terminally differentiated effector memory CD81 T cells) than in naive CD81 T cells. When SLE patients and controls were compared, we observed the same alteration in total CD81 T cells. There was a trend toward decreased expression of perforin and GzmB, while expression of GzmA was increased in SLE effector memory and terminally differentiated Figure 2 . Reduction in signaling lymphocytic activation molecule family member 7 (SLAMF7) expression on CD81 T cells from SLE patients compared to those from healthy controls. SLAMF7 expression was assessed by flow cytometry on T cells isolated from peripheral blood. A, Frequency of SLAMF7 expression on CD41, CD81, and double-negative T cells isolated from SLE patients and controls. B, Correlation of SLAMF7 expression with disease activity. SLAMF7 expression in patients with inactive SLE (SLEDAI score of ,4), patients with active SLE (SLEDAI score of $4), and healthy controls is shown. C, Frequency of SLAMF7 expression on naive, central memory, effector memory, and terminally differentiated effector memory CD81 T cells in SLE patients and healthy controls. D, SLAMF7 expression on central memory, effector memory, and terminally differentiated effector memory CD81 T cells in patients with inactive SLE, patients with active SLE, and healthy controls. Symbols represent individual subjects (n 5 16-27 SLE patients and 13-22 controls). In A and C, horizontal lines with bars show the mean 6 SEM. In B and D, bars show the mean 6 SEM. * 5 P , 0.05; ** 5 P , 0.01; *** 5 P , 0.001. See Figure 1 for other definitions.
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effector memory CD81 T cell subsets (see Supplementary Figure 6 , available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/doi/10.1002/ art.40038/abstract).
SLAMF7 engagement restores the antiviral CD81 T cell response that is impaired in SLE patients. To examine the degranulation capacity of CD81 T cells in response to viral antigens, we stimulated PBMCs isolated from SLE patients (n 5 8) or healthy individuals (n 5 8) with a mixture of major histocompatibility complex class Irestricted T cell epitopes from human CMV, EBV, and influenza virus (CEF) (7, 24, 25) . PBMCs were stimulated with or without anti-SLAMF7 mAb. Cells were stained for CD3, CD8, CD107a (lysosome-associated membrane protein 1, a marker of degranulation), and IFNg, and examined for the proportion of CD81 T cells that were CD107a/ IFNg double positive, a population that has been associated with antiviral protective immunity (26, 27) . SEB was used as a positive control.
SLAMF7 engagement with a specific mAb increased the response of CD81 T cells to CEF stimulation by enhancing the frequency of CD81 CD107a/IFNg double-positive T cells (Figure 4 ). Compared to healthy controls, SLE patients had fewer CD81 CD107a/IFNg double-positive T cells in response to CEF (Figure 4 ). In the presence of anti-SLAMF7 mAb, the frequency of SLE CD81 CD107a/IFNg double-positive T cells in response to CEF stimulation was restored to levels comparable to those observed in healthy controls (Figure 4) . SLAMF7 engagement enhances the cytolytic activity of CD81 T cells in response to viral antigens. Because SLAMF7 engagement favors CD81 T cell degranulation When CEF-expanded CD81 T cells were activated with anti-SLAMF7 mAb instead of an isotype control prior to coculture with target CD41 T cells, lysis of CEF-loaded autologous target CD41 T cells was significantly increased ( Figure 5 ). In samples from SLE patients, treatment with anti-SLAMF7 mAb, compared to treatment with an isotype control, also enhanced effector CD81 T cell lysis of target cells in response to CEF peptide ( Figure 5C ). SLAMF7-mediated enhancement of target cell lysis in response to CEF peptides was similar in SLE patients and controls ( Figures 5B and C) . In summary, SLAMF7 engagement enhanced CD81 T cell cytotoxicity in response to viral antigenic peptides.
DISCUSSION
In this study, we showed that the distribution of differentiated CD81 T cell subsets was altered in peripheral blood from SLE patients. This skewed CD81 T cell distribution was mainly characterized by a decreased number of effector memory CD81 T cells, a subset of CD81 cells that produce effector cytokines, such as IFNg, and rapidly become cytotoxic upon antigenic challenge (29) . This subset is poised for a rapid response at the onset of a microbial infection (30) . Central memory CD81 T cells are also decreased in the peripheral blood of patients with active SLE. Central memory cells primarily home to lymph nodes, and their main role is to proliferate and generate effector cells upon antigen stimulation (29) . The reason CD81 T cell distribution is altered in SLE remains unknown. One explanation could be that effector CD81 T cells tend to become double-negative (CD31CD42CD82) T cells, a subset that has been linked to SLE immunopathogenesis, in the context of continuous antigenic stimulation and chronic inflammation (31) .
The reduced frequency of effector memory and central memory CD81 T cells in patients with SLE may contribute to the increased infection rates seen in lupus patients (6) (7) (8) . Furthermore, the effector function of CD81 T cells (cytotoxic activity and cytokine production), which is considered a hallmark of antiviral protective immunity, is compromised in SLE (7, 26) . Expression of the cytolytic enzymes perforin, GzmA, and GzmB is dysregulated in CD81 T cells from SLE patients compared with CD81 T cells isolated from healthy individuals. CD81 T cells from patients with SLE display significantly decreased levels of perforin and GzmB, whereas levels of GzmA appear to be slightly elevated. Perforin and GzmB are associated with the cytotoxic activity of effector CD81 T cells (32) . GzmA is much less cytotoxic than GzmB and is more likely involved in the proinflammatory process, since it activates monocytes to secrete inflammatory mediators and cleaves IL-1b from a propeptide to its activated form (33, 34) . Elevated levels of GzmA have been observed in the plasma and synovial fluid of rheumatoid arthritis patients, and in the blood of patients with chronic viral infection or allergic diseases (35) . Increased levels of GzmA in SLE patients may represent a response to the underlying inflammation.
Moreover, the proportion of CD81 T cells that are positive for both CD107a and IFNg is reduced following stimulation of SLE PBMCs with viral antigens, thus further underscoring the defective effector function of SLE CD81 T cells. This is consistent with our previous study showing that degranulation of CD81 T cells in response to anti-CD3 stimulation is decreased in SLE (7).
In both healthy controls and SLE patients, the presence of SLAMF7 defines cytotoxic effector CD81 T cells. The cytolytic enzymes perforin, GzmA, and GzmB are restricted to the SLAMF71 CD81 T cell population. Compared to CD81 T cells isolated from healthy controls, expression of SLAMF7 is decreased in SLE CD81 T cells. Reduced SLAMF7 expression was observed in each CD81 memory cell subset (central memory, effector memory, and terminally differentiated effector memory cells). This difference of expression was more prominent in patients with active SLE.
The role of SLAMF7 has been extensively studied in patients with multiple myeloma, where ligation of SLAMF7 has been suggested to promote NK cytotoxicity and antibody-dependent cell-mediated cytotoxicity followed by a significant clinical benefit. In this study, we demonstrated that engagement of SLAMF7 with a specific anti-SLAMF7 antibody promotes CD81 T cell degranulation, cytokine production, and cytotoxicity in response to viral peptides. Interestingly, even though SLAMF7 expression is decreased in SLE patients, its engagement enabled the restoration of degranulation, IFNg production, and cytotoxic activity to levels comparable to those in controls. 1042 COMTE ET AL Our data also suggest that enhancement of CD81 T cell effector function in response to antigen may be a part of the mechanism leading to a favorable antitumor response in patients treated with anti-SLAMF7 mAb (36) . It would be of interest to assess whether SLAMF7 ligation can expand the CD81 T cell response against tumor antigens in patients with multiple myeloma or other tumors. Moreover, in NK cells, SLAMF7 has been shown to recruit the SH2 adaptor protein EAT-2 to initiate the cytotoxic signaling cascade (11, 37) . We did not detect EAT-2 expression in CD81 SLAMF71 T cells, suggesting that NK cells and CD81 T cells use different pathways to promote cytotoxic response to SLAMF7 engagement. Whether SLAMF7-initiated responses in CD81 T cells are mediated via SLAMF-associated protein or via other adaptor molecules remains to be determined.
The reason SLAMF7 expression is decreased in CD81 T cells from SLE patients is not clear. In this study, we did not address the molecular mechanisms responsible for the decrease in SLAMF7 expression in SLE CD81 T cells. An important question regarding this abnormality is whether the decrease in SLAMF7 expression is a primary defect related to the disease itself or an alteration that occurs at the onset of chronic inflammation, which may limit SLAMF7 protein formation or accelerate protein degradation. In this context, persistent antigen stimulation or chronic exposure to proinflammatory cytokines may contribute to SLAMF7 down-regulation. A genetic predisposition contributing to decreased SLAMF7 expression on SLE CD81 T cells cannot be excluded either, since the SLAMF-containing locus 1q23 has been associated with lupus in both humans and mice (38, 39) .
Overall, our data suggest that SLAMF7 engagement restores to normal levels the defective effector function of CD81 T cells in SLE. Correction of the CD81 T cell antiviral responses in SLE patients should decrease the rate of infections and reduce morbidity and mortality.
